Standard Maintenance [POMP/D (Methotrexate, 6 - Mercaptopurine, Vincristine, Prednisone/Dexamethasone)] Plus Ixazomib Maintenance Therapy in Adults With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Mercaptopurine; Methotrexate; Prednisone; Vincristine
- Indications Acute biphenotypic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 13 Feb 2018 Planned End Date changed from 1 Mar 2020 to 13 Feb 2018.
- 13 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 13 Feb 2018.
- 13 Feb 2018 Status changed from recruiting to withdrawn prior to enrolment.